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Objective: Angioplasty and stenting are options for revascularization of symptomatic femoral popliteal disease. Although
angioplasty alone is effective in short lesions, longer lesions are often treated with stents. Multiple overlapping stents are
expensive and may be associated with stent fracture. This trial evaluated the safety and efﬁcacy of a single self-expanding
stent up to 20 cm in length in patients with atherosclerotic disease of the superﬁcial femoral artery (SFA) and proximal
popliteal artery.
Methods: Patients with lesions >4 cm and <18 cm were enrolled in this nonrandomized, prospective, multicenter trial that
evaluated the Protégé EverFlex Self-Expanding Peripheral Stent System (Covidien, Plymouth, Minn). The study’s
primary end points were the 30-day major adverse event rate and duplex ultrasound-assessed patency at 1 year. These
were compared with published performance goals. A preplanned analysis was conducted for the primary effectiveness end
points at 1 year. Follow-up, including history, ankle-brachial index, patient-reported outcomes, duplex ultrasound
assessment, and radiographs, is planned through 3 years. There was core laboratory review of angiograms, ultrasound
scans, and plain radiographs. A subgroup of patients was studied with graded treadmill testing.
Results: The study enrolled 287 patients (66% male; mean age, 68 years) with stenotic, restenotic, or occluded lesions of
the SFA at 44 investigational sites in the United States and Europe. Systemic comorbidities included hypertension (88%),
hyperlipidemia (86%), diabetes (43%), and prior SFA intervention (41%). The mean lesion length measured by the core
laboratory was 89 mm. The mean normal-to-normal lesion length measured by sites was 110 mm. A total of 303 stents
were implanted, and 95% of patients received a single stent. No major adverse events occurred at 30 days. At 1 year,
primary outcome of duplex ultrasound stent patency was 67.7% in evaluable patients, and among 1-year secondary
outcomes, the mean ankle-brachial index increased by 0.25. Walking Improvement Questionnaire scores improved in pain
by 33.7, distance by 37.1, speed by 18.6, and stair climbing by 24.7. The Kaplan-Meier estimate of primary patency was
77.2%, primary assisted patency was 86.9%, and secondary patency was 87.3%. Rutherford clinical category improved in
83.5% of patients. Stent fracture rate was 0.4%. Matched absolute claudication distance was 412 feet greater and was not
statistically different in this subgroup of 29 individuals.
Conclusions: The results of DURABILITY II (StuDy for EvalUating EndovasculaR TreAtments of Lesions in the
Superﬁcial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol Stent SYstem II) suggest that
a new single stent strategy is safe and effective for the treatment of long lesions of the SFA and proximal popliteal arteries
at 1 year. (J Vasc Surg 2013;58:73-83.)Endovascular treatment is commonly performed as recommended endovascular treatment, including percuta-
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Fig 1. A, Protégé EverFlex Self-Expanding Peripheral Stent cut in
an open lattice design showing spiral cell connectors, three-wave
peaks, peak-to-peak connection nodes, and tantalum markers at
the proximal and distal ends of the stent; available in stent lengths
of 20, 30, 40, 60, 80, 100, 120, 150, and 200 mm. B, A 200-mm
stent is depicted.
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associated with favorable outcomes in short lesions, partic-
ularly those <40 mm in length, but longer lesions have
demonstrated poorer results after PTA.2-9
Nitinol stent implantation after balloon angioplasty is
commonly used to treat the problems of early elastic recoil,
residual stenosis, and ﬂow-limiting dissection and has been
used for the treatment of longer and more complex lesions
than in lesions treated with PTA alone. Initial randomized
controlled trials reported from 1997 to 2003 failed to show
beneﬁt of a balloon-expandable stainless-steel stent over
angioplasty alone,2-6 but recent studies using self-
expanding nitinol stents have shown better outcomes of
primary stenting than with PTA alone, with primary
patency rates as high as 81% at 1 year.7,8,10
The purpose of DURABILITY II (StuDy for EvalU-
ating EndovasculaR TreAtments of Lesions in the Superﬁ-
cial Femoral Artery and Proximal Popliteal By usIng the
Protégé EverfLex NitInol Stent SYstem II) was to evaluate
the safety and effectiveness of primary stenting using the
Protégé EverFlex Self-Expanding Peripheral Stent System
(Covidien, Plymouth, Minn; Fig 1) in the superﬁcial
femoral artery (SFA) and proximal popliteal artery in
patients with symptomatic PAD. It was hypothesized that
a single, longer stent would support treatment of longer
lesions, leading to favorable patency results with a low
rate of stent fracture.
METHODS
This study was conducted under an investigational
device exemption using a protocol approved by the U.S.
Food and Drug Administration (FDA).
Study design. DURABILITY II is a prospective,
multicenter, single-arm study to evaluate PTA and
primary stenting using a single self-expanding nitinol stent
compared with PTA alone in the treatment of atheroscle-
rotic SFA lesions, including long lesions up to 180 mm, in
symptomatic patients. The outcomes were compared with
performance goals modiﬁed from those developed by
VIVA (Vascular InterVentional Advances) Physicians Inc
(VPI) and promulgated in cooperation with the FDA. The
VPI performance goals were based on data from ﬁve
published randomized trials and three industry PTA trials,
and according to the agreement with the FDA, they
provide a basis for evaluation of stenting outcomes in
single-arm trials that require a demonstration of beneﬁt
exceeding that obtained with PTA alone based on historic
data.11,12 DURABILITY II is the ﬁrst trial to use these
guidelines in its study design.
Inclusion and exclusion criteria are listed in Table I.
Before patient enrollment, each investigational site was
required to obtain Institutional Review Board approval,
and signed informed consent was required of all patients.
The study included independent oversight of safety,
including adverse events, as well as independent evaluation
of study outcomes. A Clinical Events Committee (CEC)
composed of independent physicians adjudicated adverse
events, and a Data Safety Monitoring Board (DSMB),which included a biostatistician and independent physi-
cians, reviewed study data and monitored safety. Angio-
graphic, radiographic, and duplex ultrasound core
laboratories analyzed all procedural and follow-up images.
In general, data are reported as adjudicated by the core
laboratories except for lesion length, for which both core
laboratory and site data are shown. The clinical sites used
a “normal-to-normal” deﬁnition of lesion length,
measuring from healthy tissue to healthy tissue, whereas
the angiographic core laboratory measured “20-to-20”
lesion length, between the proximal and distal points at
which the lesion was 20% stenosed. These two methods
represent standard practice by the clinical sites and the
core laboratory, respectively, and have been similarly re-
ported elsewhere.13
Patient assessment. Medical history was obtained
before the procedure, including concomitant medication
use, Rutherford clinical category, rest ankle-brachial index
(ABI), the Walking Impairment Questionnaire (WIQ), and
laboratory results for serum creatinine and white blood cell
count. ABI, WIQ scores, and medications were also
recorded at the 30-day, 1-year, 2-year, and 3-year follow-
up visits, along with duplex ultrasound assessments. Angi-
ography was performed during the index procedure, and
the Rutherford clinical category was reassessed at 30 days
and at 1 year.
Adverse event evaluation was performed at the end of
the index procedure and at each follow-up visit. X-ray
imaging for evaluation of stent fractures was performed at
1, 2, and 3 years. In early versions of the study protocol,
absolute claudication distance by graded treadmill test
was required before the procedure and at 1 year; however,
this requirement was removed in a subsequent protocol
revision because of difﬁculties with recruitment and
compliance. Follow-up to 3 years was planned to permit
assessment of intermediate-term patency and stent fracture
rates, which will be reported when follow-up is completed.
Table I. Inclusion and exclusion criteria
Inclusion criteria
General inclusion criteria
Participants must meet all of the following general inclusion criteria.
1. Has stenotic, restenotic (from PTA or adjunct therapy, not including stents or stent grafts), or occluded lesion(s) located in the
native SFA or SFA and proximal popliteal arteries suitable for primary stenting.
2. Has a Rutherford Clinical Category Score of 2, 3, or 4.
3. Is willing to comply with all follow-up evaluations at the speciﬁed times.
4. Is aged $18 years.
5. Provides written informed consent before enrollment in the study.
Angiographic inclusion criteria
Participants must meet all of the following angiographic inclusion criteria. The implanting physician bases all angiographic inclusion
criteria on visual determination at the time of the procedure.
1. Target lesion(s) located within the native SFA/proximal popliteal: distal point at least 3 cm above the cortical margin of the femur
and proximal point at least 1 cm below the origin of the profunda femoralis measured by straight posteroanterior view for distal
lesions, ipsilateral oblique view for proximal lesions.
2. Evidence of $50% stenosis or restenosis (from PTA or adjunct therapy, not including stents or stent grafts), or occlusion of target
lesion(s).
3. Target lesion(s) total length is $4 cm and #18 cm as determined by a spatially calibrated internal measurement using a device with
known distance between radiopaque markers (eg, marker catheter, balloon catheter, marker wire) and is amenable to stenting with
a single stent.
4. Target vessel diameter is $4.5 mm and <7.5 mm.
5. There is evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not also require treatment for
signiﬁcant (>50% stenosis or occlusion) stenosis during the index procedure.
Exclusion criteria
General exclusion criteria
The participant must not meet any of the following general exclusion criteria.
1. Has undergone previous implantation of stent(s) or stent graft(s) in the target vessel.
2. Has a contraindication or known allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, contrast media, or any other drug
used in study according to the protocol.
3. Has known hypersensitivity to nickel-titanium.
4. Has bleeding diathesis, coagulopathy, known hypercoagulable condition, or refuses blood transfusion.
4. Is female with childbearing potential not taking adequate contraceptives or currently breastfeeding.
5. Has life expectancy of <1 year.
6. Has planned use of cutting balloon, scoring balloon, thrombectomy, atherectomy, brachytherapy, or laser devices during procedure.
7. Has previously been enrolled in the DURABILITY II study.
8. Has received endovascular treatment of target lesion within 6 months of the index procedure.
9. Has any planned surgical intervention or endovascular procedure 14 days before or 30 days after the index procedure.
10. Is currently participating in an investigational drug or another device study that has not completed the primary end point or that
clinically interferes with the current study end points.
11. Has one of the following comorbid conditions:
A History of severe liver disease (ie, ascites, esophageal varices, liver transplant)
A Known or suspected active infection
A Undergoing hemodialysis for kidney failure
A Undergoing immunosuppressant therapy
A Creatinine level on most recent test (>2.5 mg/dL)
A New York Heart Association classiﬁcation of III or IV with hospitalization for decompensated heart failure within 3 months
A Recent (within 30 days) myocardial infarction
A Recent (within 30 days) hemorrhagic or ischemic stroke
A Acute thrombophlebitis or deep venous thrombosis in the limb to be treated
A Any other comorbid condition that in the judgment of the physician precludes safe percutaneous intervention
12. Has symptomatic contralateral femoral disease.
Angiographic exclusion criteria
1. Exchangeable guidewire cannot cross the target lesion and re-enter true vessel lumen distal to lesion(s).
2. Presence of signiﬁcant (>50% stenosis or occlusion) ipsilateral common femoral stenosis.
3. Aneurysmal target vessel.
4. Presence of an acute intraluminal thrombus at the proposed lesion site.
5. Perforation, dissection or other injury of the access or target vessel requiring additional stenting or surgical intervention prior to start
of PTA procedure.
6. Focal popliteal disease in the absence of femoral disease.
DURABILITY II, StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superﬁcial Femoral Artery and Proximal Popliteal By usIng the Protégé
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Table II. Source of Vascular InterVentional Advances (VIVA) data
Variable No.
Safety #30 days, % (No.) Effectiveness, % (No.)
Death Amputation TVR Compositea 12-month patency
Company A 29 0.0 0.0 0.0 0.0 12 (3/25)
Company B 24 4.2 (1/24) 0.0 4.2 (1/24) 8.3 (2/24) 17 (1/6)
Company C 63 0.0 0.0 7.9 (5/63) 7.9 (5/63) 36 (20/55)
Combined 116 0.0 (1/116) 0.0 6.0 (7/116) 6.0 (7/116) 28 (24/86)
Literature review 203 e e e e 37 (71/191)
Overall results 6.0 e e e 33.0
Performance goal 12.0 e e e 66.0
TVR, Target vessel revascularization.
aAssessed as death, amputation, and TVR.
Table III. Patient demographics and characteristics
Characteristics Outcome
Age, years
Mean 6 SD (No.) 67.7 6 10.7 (287)
Minimum-maximum 39.4-93.3
Male, % (No.) 66.2 (190/287)
Race, % (No.)
White/Caucasian 88.9 (255/287)
African 7.7 (22/287)
Asian 0.7 (2/287)
Hispanic 2.4 (7/287)
Other 0.3 (1/287)
Risk factors, % (No.)
Diabetes 42.5 (122/287)
Type 1 3.1 (9/287)
Type 2 39.4 (113/287)
Hyperlipidemia 86.1 (247/287)
Hypertension 88.2 (253/287)
Renal insufﬁciency 9.8 (28/287)
Current smoker 39.0 (112/287)
Medical history
Angina 17.4 (50/287)
Arrhythmia 13.9 (40/287)
Congestive heart failure 9.4 (27/287)
Stroke 6.3 (18/287)
Transient ischemic attack 4.9 (14/287)
Myocardial infarction 20.9 (60/287)
Nonhealing ischemic ulcer in the
lower extremities
1.4 (4/287)
Amputation of the lower extremities
(nontarget limb)
1.0 (3/287)
Previous interventions in the SFAs or
popliteal arteries
41.1 (118/287)
Clinical characteristics
Rutherford Clinical Category, % (No.)
2 ¼ Moderate claudication 39.4 (113/287)
3 ¼ Severe claudication 55.7 (160/287)
4 ¼ Ischemic rest pain 4.5 (13/287)
5 ¼ Minor tissue loss 0.3 (1/287)
Ankle-brachial index
Mean 6 SD (No.) 0.69 6 0.19 (281)
Minimum-maximum 0.06-1.38
SD, Standard deviation; SFA, superﬁcial femoral artery.
Table IV. Lesion characteristics
Lesion characteristics Outcome
SFA location, % (No.)
Proximal 27.5 (79/287)
Distal 70.4 (202/287)
Popliteal 2.1 (6/287)
Lesion length, mm
20-to-20 method
Mean 6 SD (No.) 89.1 6 44.8 (287)
Minimum-maximum 7.3-200.9
Normal-to-normal methoda
Mean 6 SD (No.) 109.6 6 45.0 (287)
Minimum-maximum 10.0-180.0
Preprocedure variables
Reference vessel diameter, mm
Mean 6 SD (No.) 4.8 6 0.9 (287)
Minimum-maximum 2.7-8.0
Minimum lumen diameter, mm
Mean 6 SD (No.) 0.7 6 0.8 (287)
Minimum-maximum 0.0-2.7
Diameter stenosis, %
Mean 6 SD (No.) 85.8 6 16.2 (287)
Minimum-maximum 50.7-100.0
Occlusion 48.1 (138/287)
Calciﬁcation, % (No.)
None/mild 30.0 (86/287)
Moderate 26.8 (77/287)
Severe 43.2 (124/287)
Ulcerated 10.5 (30/287)
Aneurysm 1.0 (3/287)
SD, Standard deviation; SFA, superﬁcial femoral artery.
aNormal-to-normal lesion length as assessed by the site investigator.
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receive an oral, once-daily dose of 325 mg aspirin (or 81
mg if they were unable to tolerate 325 mg), before and
after the procedure, and 75 mg clopidogrel daily for 7 days
before the procedure, 300 mg for 3 days before theprocedure, or 600 mg within 24 hours before or imme-
diately after the procedure, and 75 mg daily for a minimum
of 4 weeks after the procedure. If the patient was intolerant
of clopidogrel, ticlopidine was acceptable.
Heparin anticoagulation was required to maintain an
activated clotting time of >200 seconds if a glycoprotein
IIb/IIIa inhibitor was used, or >250 seconds if a glycopro-
tein IIb/IIIa inhibitor was not used.
Patients who met all inclusion criteria and no exclusion
criteria were enrolled once an exchangeable guidewire
crossed the target lesion(s) and re-entered the true vessel
lumen distal to the target lesion. An angioplasty balloon
of an appropriate diameter and length was used for vessel
predilatation before stent deployment. Although the intent
Fig 2. Kaplan-Meier estimate of freedom from loss of primary patency deﬁned as peak systolic velocity (PSV)
ratio <2.0 and no clinically driven reintervention within the stented segment. # At Risk gives the number of patients at
risk of an event at the start of the interval, whereas # Censored and # Events are the incremental counts of patients
censored or with events during the interval. CI, Conﬁdence interval.
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with a single study stent, multiple stents were used as clin-
ically indicated at the investigator’s discretion and was not
considered a protocol deviation.
Study device. The EverFlex stent is made of a nickel-
titanium (nitinol) alloy and deployed through a 6F, 0.035-
inch over-the-wire delivery system. The EverFlex stent is
cut from a nitinol tube in an open-lattice design, with
proximal and distal tantalum radiopaque markers. Upon
deployment, the stent achieves its predetermined diameter
and exerts a constant, radial force to establish patency.
Multiple lengths (20, 30, 40, 60, 80, 100, 120, 150, and
200 mm) and diameters (6, 7, and 8 mm) were available.
Standard PTA techniques were followed for balloon dila-
tation after stent deployment.
Study end points. The primary safety end point was
the major adverse event (MAE) rate at 30 days, deﬁned as
clinically driven target lesion revascularization (TLR),
deﬁned as $50% diameter stenosis in the presence of recur-
rent symptoms or a$70% stenosis associated with decreased
ABI$0.15 from baseline, amputation of the treated limb, orall-cause mortality. The primary effectiveness end point was
the primary stent patency rate at 1 year, deﬁned as a duplex
ultrasound peak systolic velocity ratio<2.0 as adjudicated by
the independent core laboratory and no clinically driven
reintervention within the stented segment. Peak systolic
velocity ratio is calculated as the ratio of the peak systolic
velocity at the location of the stenosis divided by the value in
normal tissue proximal to the stenosis; the cutoff of 2.0 was
selected in keeping with the VIVA performance goals. Data
used to establish the VIVA goals are reported in Table II.
Secondary safety end points included the MAE rate
and stent fractures at 1 year and the change in Rutherford
clinical category at 30 days compared with baseline. The
secondary effectiveness end point included primary patency
in the subgroup that received a single stent; device success,
deﬁned as the ability to deploy the stent as intended at the
treatment site; change in Rutherford clinical category at 1
year; change in ABI at 1 year; assisted primary patency
and secondary patency at 1 year; and change in absolute
claudication distance, as measured by treadmill testing,
and change in WIQ results at 1 year.
Table V. Major adverse events (MAEs) at 1 year
1-year MAEs N ¼ 273a
Patients with MAE at 1 year, % (No.)
[even count]
16.8 (46/273) [50]
Death, % (No.) [even count] 2.9 (8/273) [8]
Amputation of treated limb, % (No.)
[even count]
0.0 (0/273) [0]
Clinically driven TLR, % (No.)
[even count]
13.9 (38/273) [42]
TLR, Total limb revascularization.
aDenominator for 1-year MAEs included patients who had completed the
1-year follow-up visit, or who had not completed the visit but whose 1-year
visit window had closed, or those who did not complete the 1-year visit but
had had an MAE before 1 year.
Table VI. Improvement in Rutherford Clinical Category
at 1 year
Variable Baseline 1 year
Rutherford Clinical
Category, % (No.)
0 ¼ Asymptomatic 0.0 (0/287) 55.9 (146/261)
1 ¼ Mild claudication 0.0 (0/287) 16.5 (43/261)
2 ¼ Moderate
claudication
39.4 (113/287) 18.4 (48/261)
3 ¼ Severe claudication 55.7 (160/287) 8.8 (23/261)
4 ¼ Ischemic rest pain 4.5 (13/287) 0.0 (0/261)
5 ¼ Minor tissue loss 0.3 (1/287) 0.4 (1/261)
6 ¼ Major tissue loss 0.0 (0/287) 0.0 (0/261)
Mean 6 SD (No.) 2.7 6 0.6 (287) 0.8 6 1.1 (261)
Minimum-maximum 2.0-5.0 0.0-5.0
Changes from baseline
Percentage with
improvement of
1 or more categories,
% (No.)
e 83.5 (218/261)
1 category, % (No.) e 19.5 (51/261)
2 categories, % (No.) e 29.5 (77/261)
3 categories, % (No.) e 31.8 (83/261)
4 categories, % (No.) e 2.7 (7/261)
Percentage with
No change, % (No.) e 14.9 (39/261)
Worsening of 1
category, % (No.)
e 1.5 (4/261)
Mean 6 SD (No.) e 1.8 6 1.2 (261)
Minimum-maximum e 4.0 to 1.0
SD, Standard deviation.
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ating primary safety was computed based on a one-sided
a ¼ .025 and desired power of 80%, assuming an MAE
rate of 6% against the VIVA performance goal of 12%.
Similarly, a sample size of 232 for evaluating primary
effectiveness was obtained from a one-sided a ¼ .025 and
desired power of 80%, assuming a primary patency of 66%
against a modiﬁed performance goal of 57%, which took
into account the expectation of longer-treated lesions than
those recorded in the original VIVA analysis. The larger of
these two sample sizes (n ¼ 232) was adjusted for loss to
follow-up of up to 10% and a potential 10% rate of mul-
tistent implantations, resulting in a total of 287 patients.
Primary analysis of all baseline characteristics and study
outcomes was based on all available data from all enrolled
participants, unless otherwise indicated. Discrete variables
are presented using frequency distributions and cross-
tabulations, and continuous variables are summarized by
presenting the number of observations, mean and standard
deviation, and median with minimum and maximum
values. Patient counts, not event counts, were used for
rhe primary analysis for adverse event reporting, which
includes the primary and secondary safety end points. A
patient with more than one event was counted only once
toward the event rate based on the total number of partic-
ipants with adverse events. Comparisons of continuous
variables were made with t-tests when the assumption of
normality was not violated, and categoric variables were
assessed using Pearson c2 or the Fisher exact test, as appro-
priate. Kaplan-Meier analysis was used to evaluate time-to-
event data, including the primary effectiveness end point.
Two-sided P values of <.05 and one-sided P values
of <.025 were deemed statistically signiﬁcant.
RESULTS
Patient characteristics. The study enrolled 287
patients at 40 U.S. sites and four European sites between
October 2007 and April 2010. Patient characteristics
were consistent with the intended study population and
are summarized in Table III. The mean age was 68 years,
and 66% were men. The most common pre-existing risk
factors were hypertension (88%), hyperlipidemia (86%),and diabetes (43%), and 41.1% of patients had undergone
previous interventions in the SFA or popliteal arteries,
including 8.0% with previous interventions in the target
limb for this study.
Procedural results. A total of 303 stents were
implanted in 287 patients, each of whom had a target
lesion identiﬁed in the SFA. A single stent was used in
95% of participants, and 29.4% of the stents implanted
were 200 mm in length. The mean lesion length was
109.6 6 45.0 mm by the normal-to-normal site method
and 89.1 6 44.8 mm by the 20-to-20 method. The
angiographic core laboratory determined the minimum
lumen diameter before stenting was 0.7 6 0.8 mm and
percentage diameter stenosis was 85.8% 6 16.2%,
including 48.1% occluded lesions and 43.2% severely
calciﬁed lesions. The mean postprocedural minimum
lumen diameter was 4.0 6 0.8 mm, and percentage
diameter stenosis was 17.8% 6 10.3%, also by the core
laboratory assessment. Details of preprocedural lesion
characteristics are summarized in Table IV.
Primary end points. Primary safety end point data
were available for 284 patients. The analysis excluded
three patients without reported MAEs and who did not
complete 30-day follow-up. There were no MAEs #30
days, and the 97.5% upper conﬁdence bound of 1.1% met
the predeﬁned performance goal of 12%.
At 1 year, 253 patients had evaluable patency informa-
tion deﬁned as a core laboratory-assessed diagnostic duplex
ultrasound evaluation of the stented arterial segment or the
Fig 3. Kaplan-Meier estimate of freedom from loss of assisted primary patency deﬁned as peak systolic velocity (PSV)
ratio <2.0 maintained by repeated percutaneous intervention completed before complete vessel occlusion. # At Risk
gives the number of patients at risk of an event at the start of the interval, whereas # Censored and # Events are the
incremental counts of patients censored or with events during the interval. CI, Conﬁdence interval.
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were conducted outside the protocol-deﬁned visit window
in 27 patients; according to the end point deﬁnition, these
results were not included in the primary effectiveness end
point. An additional 34 patients did not have evaluable
12-month patency data due to death, study withdrawal,
or loss to follow-up, missed visit, or a nondiagnostic duplex
ultrasound scan. The primary stent patency in the 226
qualifying patients, according to the above criteria, was
67.7%, with a 97.5% lower conﬁdence bound of 61.2%,
meeting the predeﬁned performance goal of 57%.
Primary patency was also evaluated by the Kaplan-
Meier time-to-event method, as shown in Fig 2. For this
analysis, the time to loss of patency was evaluated for all
patients irrespective of the timing of their follow-up visits,
thereby incorporating all available data. Under this
method, freedom from loss of primary patency at 1 year
was 77.2% (Fig 2). Further post hoc subgroup analysis
showed that freedom from loss of primary patency was
86.2% in lesions #80 mm in length and 69.6% in lesions>80 mm, a statistically signiﬁcant difference (P ¼ .002).
Patency at 1 year was also analyzed by reference vessel
diameter, with the following results: 83.6% for #4 mm,
73.2% for 4 to 5 mm, and 79.3% for >5 mm (P ¼ .292).
Patency at 1 year was evaluated by baseline Rutherford
class as 79.9% for class 2, 74.1% for class 3, and 92.3%
for class 4 (P ¼ .393).
Secondary end points. The 1-year MAE rate was
16.8% (Table V), including eight deaths and 38 patients
with a TLR. The CEC adjudicated that all TLRs were
clinically driven and that all deaths were classiﬁed as
unrelated to the stent. A single stent fracture had occurred
at 1 year, which was assessed as a clinically relevant class V
(transaxial spiral conﬁguration fracture) by the stent frac-
ture adjudication committee.
A single stent was implanted in 272 patients, of whom
217 had qualifying data according to the same assessment
rules as noted above. The 1-year primary patency was
68.7% vs 67.7% in the full cohort. The proportion of
asymptomatic patients (Rutherford clinical category 0)
Fig 4. Kaplan-Meier estimates of freedom from loss of secondary patency. Secondary patency was deﬁned as peak
systolic velocity (PSV) ratio <2.0 maintained by repeat percutaneous intervention after occlusion of the target lesion. #
At Risk gives the number of patients at risk of an event at the start of the interval, whereas # Censored and # Events are
the incremental counts of patients censored or with events during the interval. CI, Conﬁdence interval.
Table VII. Improvement of ankle-brachial index (ABI)
at 1 year
ABI Baseline 1 year
Mean 6 SD (No.) 0.65 6 0.15 (246)a 0.89 6 0.20 (222)b
Minimum-maximum 0.06-0.89 0.25-1.77
Changes in ABI
Percentage with
Improvement,
% (No.)
e 86.5 (192/222)
No change, % (No.) e 0.9 (2/222)
Decrease, % (No.) e 12.6 (28/222)
Mean 6 SD (No.) e 0.25 6 0.23 (222)
Minimum-maximum e 0.36 to 1.21
SD, Standard deviation.
aDenominator included patients at baseline who had compressible arteries
and baseline ankle-brachial index <0.9 among the 287 enrolled patients.
bDenominator included patients at 1 year who had compressible arteries
and baseline ankle-brachial index <0.9 among the participants with 1-year
visit.
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up, and 83.5% of patients showed an improvement in
Rutherford clinical category at 1 year (Table VI). By
Kaplan-Meier methods, the 1-year assisted primary patency
was 86.9% (Fig 3) and the estimate of secondary primary
patency at 1 year was 87.3% (Fig 4). The mean ABI
increased by 0.25 from baseline (0.65) to 1 year (0.89)
and improved in 86.5% of patients (Table VII).
Matched absolute claudication distance measurements
before stenting and at 1 year, deﬁned as the total walking
distance using a graded treadmill exercise test, were avail-
able in 29 patients (Table VIII). Mean improvement of
412 feet was noted in the paired data set, which was not
statistically signiﬁcant. Walking improvement at 1 year
was deﬁned as an increase in the WIQ score. The mean
score for pain, aching, or cramps improved by 33.7 from
baseline (41.7) to 1 year (75.2). The mean walking
distance scores also increased, by 37.1 for matched pairs,
from 21.5 at baseline to 59.7 at 1 year. The walking speed
Table VIII. Absolute claudication distance improvement at 1 year
Treadmill exercise test Baseline 1 year
Absolute claudication distance, feet
Mean 6 SD (No.) 1233 6 966.8 (74) 1502 6 1812 (33)
Minimum-maximum 158.4-4224 316.8-11,088
Changes from baseline
Percentage with
Improvement, No. (%) e 69.0 (20/29)
No change, No. (%) e 3.4 (1/29)
Decrease, No. (%) e 27.6 (8/29)
Mean 6 SD (No.) e 412 6 1477 (29)
Minimum-maximum e 1584 to 7392
Table IX. Walking improvement at 1 year according to Walking Impairment Questionnaire (WIQ)
WIQ scoresa Baselineb 1 yearc
Score for pain, aching, or cramps in calves or buttocks, % max
Mean 6 SD (No.) 41.7 6 31.7 (264) 75.2 6 28.9 (241)
Minimum-maximum 0.0-100.0 0.0-100.0
Changes from baseline, % max
Mean 6 SD (No.) e 33.7 6 34.8 (239)
Minimum-maximum e 50.0 to 100.0
Walking distance score, % max
Mean 6 SD (No.) 21.5 6 25.1 (249) 59.7 6 39.6 (215)
Minimum-maximum 0.0-100.0 0.0-100.0
Changes from baseline, % max
Mean 6 SD (No.) e 37.1 6 40.6 (205)
Minimum-maximum e 93.8 to 99.2
Walking speed score, % max
Mean 6 SD (No.) 21.9 6 20.5 (227) 42.5 6 29.8 (186)
Minimum-maximum 0.0-100.0 0.0-100.0
Changes from baseline, % max
Mean 6 SD (No.) e 18.6 6 25.5 (169)
Minimum-maximum e 53.3 to 100.0
Stair climbing score (% max)
Mean 6 SD (No.) 37.8 6 31.7 (243) 65.6 6 36.2 (209)
Minimum-maximum 0.0-100.0 0.0-100.0
Changes from baseline, % max
Mean 6 SD (No.) e 24.7 6 38.3 (199)
Minimum-maximum e 79.2 to 100.0
SD, Standard deviation.
aWalking Impairment Questionnaire scoring algorithm used was described in Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking
impairment by questionnaire in patients with peripheral disease. J Vasc Med Biol 1990;2:142-52.
bBaseline denominator included participants who did not have iliac disease treated at the time of the index procedure and who had evaluable data among the
enrolled participants.
cThe 1-year denominator included patients with available WIQ data at 1 year. The denominators for “changes from baseline” included those with available
WIQ data both at baseline and at 1 year.
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(Table IX).
DISCUSSION
Stents are commonly used for treatment of femoral and
popliteal occlusive disease, particularly for longer lesions.
This clinical study is the ﬁrst to evaluate lesions up to 180
mm treated with a single stent up to 200 mm long in SFA
lesions and supported FDA approval of the study stent for
use in theSFAandproximalpopliteal artery,whichwasgranted
in March 2012. Krankenberg et al9 reported successful treat-
ment of short lesions with PTA in the Femoral Artery StentingTrial study, for which restenosis rates were comparable
between PTA and nitinol stenting (38.6% vs 31.7%, respec-
tively).However, other recent studies corroborate this patency
beneﬁt of primary stent implantation. Laird et al,10 in the
Randomized Study Comparing the Edwards Self-ExpandIng
Lifestent versus angioplasty alone In lEsions INvolving The
SFAand/orproximal popliteal artery (RESILIENT) study, re-
ported 12-month patency rates with PTA of 36.7% vs 81.3%
with primary stenting, with mean lesion lengths of 5.7 and
6.2 cm (measured on a per-lesion basis), respectively.
The Institute of Medicine has placed claudication treat-
ment strategies in the top 50 comparative effectiveness
Table X. Summary of clinical trials
Published studies Patency deﬁnition
Mean lesion
length, mm
Outcome at 12 months, % (No.)
Patency Stent fracture
ABSOLUTE1
(Absolute stent)
Based on PSVR <2.4 101 6 75 63 2 (1/49) rate assessed
per patient
FAST2 (Luminexx) Based on PSVR <2.4 45.2 6 27.9 68.3 12 (10/83) rate
assessed per patient
FESTO3 (SMART,
SelfX, and
Luminexx)
Based on PSVR <2.5 157 6 59a 41.1 in patients with
stent fractures; 84.3
in patients with no
stent fractures
37.2 (45/121) rate
assessed per limb
SIROCCO I4
(SMART)
Angiographic binary
restenosis, <50% DS
85 76.5; binary restenosis
of 23.5 at 6 months
in BMS group
18.2 (6/33) rate
assessed per patient
SIROCCO II5
(SMART)
Angiographic binary
restenosis, <50% DS
81.5 6 41.2 92.3; binary restenosis
of 7.7 at 6 months in
BMS group
8.0 (4/50) rate
assessed per patient
DURABILITY I6
(Protégé EverFlex)
Based on PSVR <2.5 96 6 27 72.2 8.1 (10/123) rate
assessed per patient
RESILIENT7
(LifeStent)
Based on PSVR <2.5
or <50% DS from
arteriography
70.5 6 44.3 81.3 3.1 (9/287) rate
assessed per stent
Zilver PTX
Randomized Trial8
(Zilver PTX)
Based on PSVR <2.0
or <50% DS from
arteriography
54.3 6 40.8 83.1 0.9 (4/457) rate
assessed per stent
BMS, Bare-metal stent; DS, diameter stenosis; FAST, Femoral Artery Stenting Trial; FESTO, Femoral Stenting in Obstructions; PSVR, peak systolic velocity
ratio; RESILIENT, Randomized Study Comparing the Edwards Self-ExpandIng Lifestent versus angioplasty alone In lEsions INvolving The SFA and/or
proximal popliteal artery; SIROCCO, Sirolimus-Coated Cordis Self Expanding Stent.
Absolute stent; Abbott Vascular, Abbott Park, Ill; Luminexx; Bard Peripheral Vascular Inc, Tempe, Ariz; SMART; Cordis Corp, Bridgewater, NJ; SelfX;
JOMED AG, Beringen, Switzerland; Protégé EverFlex; Covidien, Plymouth, Minn; LifeStent; Bard Peripheral Vascular Inc, Tempe, Ariz; Zilver PTX; Cook
Medical, Bloomington, Ind.
aReported as mean stented length.
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outcomes and patient-reported outcomes, which informs
decision making more than traditional measurement of
only patency. Differential results between strategies of
supervised exercise and aortoiliac stenting for patients
with claudication were noted by Claudication: Exercise
Vs Endoluminal Revascularization (CLEVER) investiga-
tors, who randomized 111 participants at 22 sites over
four years. Speciﬁcally, stenting was better in 6-month
WIQ and Peripheral Artery Questionnaire and pedometry
outcomes, but inferior in treadmill peak walking time.14
Another consideration is that femoropopliteal interventions
have greater risk for restenosis than aortoiliac interventions,
evidenced by the fact that no restenosis was reported in the
CLEVER study. Our study showed treadmill walking
distance improvements at 1 year, with a modest mean
improvement of 412 feet compared with an improvement
of 3.7 minutes (w650 feet at typical walking speeds for
the population in question) in peak walking time at 6
months in the stent group in CLEVER.14 Although
CLEVER studied a different group of patients with claudi-
cation who had treatment of aortoiliac inﬂow lesions, two
important similar ﬁndings are that (1) classic treadmill
testing can be discordant with patient-reported outcomes
from validated questionnaires and that (2) treadmill
improvements are modest with stenting in either territory,
and trials planning treadmill testing before and after theintervention will need to consider correspondingly appro-
priate sample sizes.
Despite the improved results seen with more recent
stent designs, one of the limitations of stenting in the
periphery is the potential for stent fracture and its implica-
tion for long-term clinical outcome. The Femoral Stent-
ing in Obstructions (FESTO) study showed a stent
fracture rate of 37.2% in long SFA lesions with three
different stents and associated reduction of primary
patency.15 Similarly, the Femoral Artery Stenting Trial
(FAST) study showed a stent fracture rate of 12% at 12
months.9 In the Sirolimus-Coated Cordis Self Expanding
Stent (SIROCCO I) study, a stent fracture rate of 18.2%
at 6 months was observed when treating lesions with
mean lesion length of 85 mm, whereas in SIROCCO II,
the 6-month fracture rate decreased to 8% under a mean
lesion length of 81.5 mm as the mean number of stents
implanted per patient decreased, suggesting that multiple
stents predispose for stent fracture.16,17 In a more recent
study with a newer nitinol stent, however, Laird et al10
reported a 12-month stent fracture rate of 3.1% in the
RESILIENT trial (Table X).
An important hypothesis tested in DURABILITY II
was the use of a single long stent for treating SFA disease.
With 95% of participants receiving a single stent, this trial
showed a stent fracture rate of 0.4% at 1 year, lower
compared with some recent studies.10,13 This improvement
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of multiple stents with overlap zones that may be at higher
risk for fracture; as previously noted, only 5% of DURA-
BILITY II patients were implanted with multiple stents
at the index procedure, whereas in RESILIENT, with
a 12-month stent fracture rate of 3.1%, 50% of participants
received multiple stents. In the Zilver PTX (Cook Medical,
Bloomington, Ind) investigation, with a 12-month stent
fracture rate of 0.9%, a mean of 1.5 stents per patient
were implanted.
This study has several limitations. It was industry-
sponsored and not randomized, although it demonstrated
superiority to predeﬁned performance goals derived from
PTA historic controls. There were few paired treadmill
patients, and the subset analysis of this functional clinical
outcome of claudication improvement is limited. Only
1-year results are reported, although follow-up is continu-
ing through 3 years; longer follow-up is needed to assess
interventions and fracture rates for these difﬁcult, long,
SFA lesions.
CONCLUSIONS
DURABILITY II demonstrated excellent 1-year results,
with a patency of 67.7% using data collected in-window and
77.2% using all data by Kaplan-Meier estimate. Long lesions
up to 180mmwere treated,with an average length of 89mm
according to core laboratory adjudication. There were no
30-day MAEs, and the stent fracture rate was 0.4% at 1
year. Objective measures of patency (duplex ultrasound
assessment and ABI) and patient-reported outcomes (WIQ
and Rutherford class) improved at 1 year compared with
baseline. Taken together, these data suggest that longer
stents, speciﬁcally designed for the SFA, provide an impor-
tant new single-stent treatment option.
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Deﬁnitions of key clinical outcomes
Diabetes (history of). Deﬁned as patients who have
been diagnosed with type 1 or type 2 diabetes and are
currently taking oral hypoglycemics or insulin.
Hypertension. Increase in systolic blood pressure
>140 mm Hg or a diastolic blood pressure >90 mm Hg.
Renal insufﬁciency. A 30% increase in serum creati-
nine from baseline.Stroke. A neurologic deﬁcit lasting >24 hours or
lasting #24 hours with a brain imaging study showing
infarction.
Transient ischemic attack (TIA). A neurologic deﬁcit
lasting <24 hours and, if an imaging study is performed,
shows no evidence of infarction.
Myocardial infarction (MI). Per the European
Society of Cardiology (ESC)/the American College of
Cardiology (ACC) deﬁnition.
